Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
1 hedge funds and large institutions have $12K invested in Antares Pharma, Inc. in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 172 closing their positions.
99% less funds holding
Funds holding: 177 → 1 (-176)
100% less funds holding in top 10
Funds holding in top 10: 4 → 0 (-4)
100% less capital invested
Capital invested by funds: $375M → $12K (-$375M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 172
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$49M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$44.7M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$35.4M |
| 4 |
SIG
Sargent Investment Group
Bethesda,
Maryland
|
-$15M |
| 5 |
State Street
Boston,
Massachusetts
|
-$14.1M |
ATRS Hedge Fund Activity: Q2 2022 in Review
1 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q2 2022, worth a combined $12K — down 100% from $375M a quarter earlier.
Sellers outnumbered buyers: 172 funds closed out of ATRS and 0 opened new positions — a net loss of 172 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was BlackRock, exiting entirely with an estimated $49M sold.
- 1 institutional investor held Antares Pharma, Inc. (ATRS) as of Q2 2022, down from 177 in Q1 2022.
- Funds reported $12K of Antares Pharma, Inc. stock for Q2 2022, down 100% quarter-over-quarter.
- 0 funds opened new Antares Pharma, Inc. positions in Q2 2022 and 172 closed out, a net change of -172 holders.
- The largest Antares Pharma, Inc. seller in Q2 2022 was BlackRock, an estimated $49M sold.
Based on aggregated 13F filings for Q2 2022.